These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 35070881

  • 1. Prognostic value of residual cancer burden and Miller-Payne system after neoadjuvant chemotherapy for breast cancer.
    Wang W, Liu Y, Zhang H, Zhang S, Duan X, Ye J, Xu L, Zhao J, Cheng Y, Liu Q.
    Gland Surg; 2021 Dec; 10(12):3211-3221. PubMed ID: 35070881
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Residual Cancer Burden Class Associated with Survival Outcomes in Women with Different Phenotypic Subtypes of Breast Cancer After Neoadjuvant Chemotherapy.
    Elder EA, Livasy CA, Donahue EE, Neelands B, Patrick A, Needham M, Sarantou T, Hadzikadic-Gusic L, Heeke AL, White RL.
    Ann Surg Oncol; 2022 Dec; 29(13):8060-8069. PubMed ID: 35980548
    [Abstract] [Full Text] [Related]

  • 7. Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.
    Pinard C, Debled M, Ben Rejeb H, Velasco V, Tunon de Lara C, Hoppe S, Richard E, Brouste V, Bonnefoi H, MacGrogan G.
    Breast Cancer Res Treat; 2020 Jan; 179(1):11-23. PubMed ID: 31529299
    [Abstract] [Full Text] [Related]

  • 8. Assessment of residual cancer burden and survival in neoadjuvant chemotherapy of inoperable stage III breast cancer: A ten-year follow-up analysis in Vietnam.
    Pham HK, Le TD, Nguyen TP, Le TU, Ta HH, Nguyen VC.
    Pathol Res Pract; 2024 Feb; 254():155099. PubMed ID: 38244433
    [Abstract] [Full Text] [Related]

  • 9. Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy.
    Hamy AS, Darrigues L, Laas E, De Croze D, Topciu L, Lam GT, Evrevin C, Rozette S, Laot L, Lerebours F, Pierga JY, Osdoit M, Faron M, Feron JG, Laé M, Reyal F.
    PLoS One; 2020 Feb; 15(6):e0234191. PubMed ID: 32579551
    [Abstract] [Full Text] [Related]

  • 10. Miller-Payne Grading and 70-Gene Signature Are Associated With Prognosis of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer After Neoadjuvant Chemotherapy.
    Wang L, Luo R, Lu Q, Jiang K, Hong R, Lee K, Zhang P, Zhou D, Wang S, Xu F.
    Front Oncol; 2021 Feb; 11():735670. PubMed ID: 34631568
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparison of Pathologic Response Evaluation Systems After Neoadjuvant Chemotherapy in Breast Cancers: Correlation With Computer-Aided Diagnosis of MRI Features.
    Choi WJ, Kim HH, Cha JH, Shin HJ, Chae EY.
    AJR Am J Roentgenol; 2019 Oct; 213(4):944-952. PubMed ID: 31237439
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of Breast Cancer Staging Systems After Neoadjuvant Chemotherapy.
    Kantor O, Laws A, Pastorello RG, King C, Wong S, Dey T, Schnitt S, King TA, Mittendorf EA.
    Ann Surg Oncol; 2021 Nov; 28(12):7347-7355. PubMed ID: 33956276
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A, Chhieng D, Giri D, Livasy C, Mies C, Rabban J, Sarode VR, Singh B, Esserman L, Chen YY.
    Breast Cancer Res Treat; 2017 Aug; 165(1):181-191. PubMed ID: 28577078
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.